Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

Fig. 2

a Hazard ratios (HR) and 95 % CI for risk of MACE+ for treatment with BIL versus comparator insulin in the individual studies. BB basal-bolus insulin therapy, BIL basal insulin peglispro, BO basal only insulin therapy, N insulin naïve prior to study, P taking insulin prior to study, T1 type 1 diabetes, T2 type 2 diabetes

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840